ProCE Banner Activity

Analysis of Nivolumab Continued Beyond Progression in Patients With R/R Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
In patients with R/R cHL who continued nivolumab treatment following progression, 53% experienced reductions in tumor burden.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology